Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL ... Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently. Show more
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in...
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at...
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -70.5 | -8.64924549135 | 815.1 | 823.56 | 736.19 | 992931 | 766.60323431 | CS |
| 4 | -207.2 | -21.7692792603 | 951.8 | 953.54 | 736.19 | 852116 | 834.28277422 | CS |
| 12 | -451.46 | -37.7455980469 | 1196.06 | 1210.97 | 736.19 | 714473 | 970.45876613 | CS |
| 26 | -235.82 | -24.052956896 | 980.42 | 1211.1999 | 736.19 | 565310 | 1011.36333952 | CS |
| 52 | -50.67 | -6.37142102682 | 795.27 | 1211.1999 | 736.19 | 536812 | 967.3245481 | CS |
| 156 | 96.02 | 14.8046501588 | 648.58 | 1211.1999 | 538.01 | 606475 | 782.19641499 | CS |
| 260 | 402.62 | 117.732031113 | 341.98 | 1211.1999 | 328.125 | 748596 | 649.94485743 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
